Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Link Pharma Chem's EBITDA for the
three
months ended in Mar. 2026 was ₹-0.9 Mil. Link Pharma Chem's Revenue for the
three
months ended in Mar. 2026 was ₹65.9 Mil. Therefore, Link Pharma Chem's EBITDA margin for the quarter that ended in Mar. 2026 was -1.40%.
Link Pharma Chem (BOM:524748) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Link Pharma Chem EBITDA Margin % Related Terms
Link Pharma Chem EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Link Pharma Chem's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Chemicals subindustry, Link Pharma Chem's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Link Pharma Chem EBITDA Margin % vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Link Pharma Chem's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Link Pharma Chem's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Link Pharma Chem (BOM:524748) has a EBITDA Margin % of -1.40% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Link Pharma Chem and its competitors. According to the industry distribution chart, Link Pharma Chem ranks #1018 out of 1577 companies in the Chemicals industry, placing it in the top 64.6%.
Is Link Pharma Chem's EBITDA Margin % too high?
Link Pharma Chem's current EBITDA Margin % is -1.40%. Based on the distribution chart, Link Pharma Chem ranks #1018 out of 1577 companies in the Chemicals industry, which is below the industry midpoint. Overall, Link Pharma Chem has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Link Pharma Chem's EBITDA Margin % compare to DOW?
According to the Chemicals industry distribution chart, Link Pharma Chem ranks #1018 out of 1577 companies for EBITDA Margin %. This places Link Pharma Chem in the lower half of its industry. The industry median EBITDA Margin % is 9.67. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Chemicals company?
The median EBITDA Margin % among Chemicals companies is 9.67, based on 1,577 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Link Pharma Chem and its competitors. For the Chemicals industry, the median EBITDA Margin % is 9.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Link Pharma Chem's current EBITDA Margin % is -1.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Link Pharma Chem stock overvalued right now?
Based on GuruFocus' analysis, Link Pharma Chem (BOM:524748) is currently considered Possible Value Trap. The stock's GF Value™ is ₹36.16, compared to a current price of ₹24.01 — trading 33.6% below its estimated fair value. The current EBITDA Margin % is -1.40%. Link Pharma Chem's overall GF Score™ is 60/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Link Pharma Chem (BOM:524748), the current EBITDA Margin % is -1.40% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Link Pharma Chem (BOM:524748) Overvalued in 2026?
Based on GuruFocus' analysis, Link Pharma Chem stock appears to be undervalued.
The current stock price of ₹24.01 is trading 33.6% below its estimated GF Value™ of ₹36.16.
GuruFocus considers Link Pharma Chem to be Possible Value Trap.
Key valuation signals for BOM:524748:
EBITDA Margin %: -1.40%
GF Value™: ₹36.16 vs. price of ₹24.01 (33.6% below fair value)
No single metric tells the full story. See the BOM:524748 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Link Pharma Chem Ltd is engaged in the manufacturing and selling of organic intermediates which are used in pharmaceuticals, agro and speciality chemical industries. The company has its manufacturing location at Nandesari in Gujarat. It operates through single segment which is Chemical manufacturing and generates revenue from the same. The company generates the majority of its revenue from domestic sales.
60GF Score
Get the complete analysis for BOM:524748
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524748 has been successfully added to your 
